Company news

BioMarin Pharmaceutical Inc. news in 2026

BioMarin Pharmaceutical Inc.'s news releases, calls and decks from 2026, newest first.

View company

BioMarin to Participate in Upcoming Investor Conferences

November 4, 2026

BioMarin Reports Third Quarter 2026 Financial and Operating Results

November 2, 2026

BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease

October 29, 2026

BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4: 30pm ET

October 26, 2026

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

October 9, 2026

BioMarin Appoints Cara Bauer as Chief People Officer

October 5, 2026

BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress

October 2, 2026

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

September 14, 2026

BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence

September 9, 2026

BioMarin Announces Close of the Alesta Therapeutics Acquisition

September 1, 2026

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea

August 29, 2026

BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline

August 18, 2026

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8: 00AM ET in Boston

August 10, 2026

BioMarin Reports Second Quarter 2026 Financial and Operating Results

August 6, 2026

BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4: 30pm ET

July 30, 2026

BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome

July 27, 2026

U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

July 13, 2026

BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026

June 16, 2026

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

May 20, 2026

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

May 18, 2026

BioMarin Reports First Quarter 2026 Financial and Operating Results

May 4, 2026

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

May 2, 2026

BioMarin Completes Acquisition of Amicus Therapeutics

April 27, 2026

BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4: 30pm ET

April 27, 2026

BioMarin Announces Board Leadership Transition

April 21, 2026

Roctavian (BioMarin Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

March 13, 2026

BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

March 12, 2026

BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Geneti...

March 11, 2026

U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

February 26, 2026

BioMarin to Participate in Four Upcoming Investor Conferences in March

February 23, 2026

BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results

February 23, 2026

BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4: 30pm ET

February 17, 2026

BioMarin Announces Closing of Private Offering of Senior Notes

February 12, 2026

BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility

January 29, 2026

BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility

January 25, 2026

BioMarin Appoints Arpit Davé Chief Digital and Information Officer

January 12, 2026

Veeva and BioMarin Form Long-Term Strategic Partnership

January 7, 2026

BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11: 15 am PT / 2: 15 pm ET, in San Francisco, CA

January 7, 2026

Calls in 2026

Decks in 2026